Published in Semin Immunopathol on February 14, 2011
Operational Tolerance in Kidney Transplantation and Associated Biomarkers. Clin Exp Immunol (2017) 0.86
Evidence for a gene controlling the induction of transplantation tolerance. Am J Transplant (2014) 0.80
Unlocking the Potential of Purinergic Signaling in Transplantation. Am J Transplant (2016) 0.77
Improvement of Liver Transplantation Outcome by Heme Oxygenase-1-Transduced Bone Marrow Mesenchymal Stem Cells in Rats. Stem Cells Int (2016) 0.76
Immunomodulatory effects of OX40Ig gene-modified adipose tissue-derived mesenchymal stem cells on rat kidney transplantation. Int J Mol Med (2016) 0.75
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 6.61
Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86
Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66
Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest (2003) 4.14
Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med (2008) 4.04
The many important facets of T-cell repertoire diversity. Nat Rev Immunol (2004) 3.83
Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59
Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol (2010) 3.56
Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest (2010) 3.41
Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A (1997) 3.25
Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18
Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 3.17
Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med (2001) 3.16
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol (2001) 2.93
Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest (2008) 2.73
Tolerance versus immunosuppression: a perspective. Am J Transplant (2008) 2.71
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant (2004) 2.35
Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int (2010) 2.28
Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant (2002) 2.18
Clinical operational tolerance after kidney transplantation. Am J Transplant (2006) 2.09
Human allograft acceptance is associated with immune regulation. J Clin Invest (2000) 1.94
Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A (1999) 1.79
Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med (2009) 1.76
Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation (2006) 1.75
T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol (2002) 1.73
Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant (2007) 1.69
Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med (2007) 1.68
Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol (2004) 1.67
Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med (1998) 1.65
Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol (2000) 1.64
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant (2003) 1.58
Characterization of γδ T cell subsets in organ transplantation. Transpl Int (2010) 1.57
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med (2007) 1.53
Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev (2009) 1.52
Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant (2003) 1.47
Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant (2004) 1.40
An appraisal of tolerance in liver transplantation. Am J Transplant (2006) 1.32
How can we measure immunologic tolerance in humans? J Am Soc Nephrol (2006) 1.29
Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol (2006) 1.28
HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation (2009) 1.23
Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J Immunol (2001) 1.16
Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation (1998) 1.14
Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant (2005) 1.09
Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation (1996) 1.03
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant (2005) 1.01
Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant (2009) 1.00
Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant (2005) 1.00
Discontinuance of immunosuprression in renal transplant patients. Arch Surg (1975) 1.00
Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol (2005) 0.95
Transplantation tolerance: lessons from experimental rodent models. Transpl Int (2007) 0.94
Immune tolerance: mechanisms and application in clinical transplantation. J Intern Med (2007) 0.94
Cessation of immunosuppressive therapy after successful transplantation: a national survey. Kidney Int (1980) 0.93
Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol (2006) 0.91
Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol (2000) 0.91
Tailoring of immunosuppression in renal and liver allograft recipients displaying donor specific T-suppressor cells. Hum Immunol (2002) 0.89
Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials. Transplantation (2009) 0.89
The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol (2008) 0.89
Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation (2009) 0.87
Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant (2006) 0.86
Tolerance assays: measuring the unknown. Transplantation (2006) 0.86
The impact of costimulatory molecule gene polymorphisms on clinical outcomes in liver transplantation. Am J Transplant (2003) 0.83
Tolerance: is it achievable in pediatric solid organ transplantation? Pediatr Clin North Am (2010) 0.81
Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol (2010) 0.79
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Transpl Immunol (2008) 0.78